Natera announced a collaboration with MEDSIR to run the MiRaDoR trial using Signatera Genome to guide treatment selection in early‑stage hormone receptor‑positive, HER2‑negative breast cancer and separately completed an acquisition of Foresight Diagnostics to add phased‑variant MRD technology. The MiRaDoR study will enroll Signatera‑positive patients into four treatment arms testing endocrine therapy and combinations with targeted agents, with serial ctDNA as the primary readout. Natera said the Foresight purchase will accelerate the company’s entry into hematologic MRD testing and improve Signatera’s sensitivity by incorporating phased‑variant enrichment and detection. Company executives framed the moves as steps to expand clinical utility of personalized ctDNA MRD assays across solid and hematologic cancers. Investigators and payers will watch whether higher sensitivity translates into actionable changes in adjuvant therapy and reimbursement. The deals underline consolidation in the MRD diagnostics market and the strategic value of sensitive ctDNA platforms for precision oncology trials.